Contribution of structural biology to clinically validated target proteins
(2008) In Drug Discovery Today 13(11-12). p.469-472- Abstract
We identified six groups of diseases expected to cause serious future health issues on the basis of a WHO report. Approved drugs for these diseases were associated with 409 target proteins; however, the percentage of selected proteins with full-length structural information deposited in the Protein Data Bank (PDB) was only 9.8%. The reason for the low percentage may be as a result of a disproportionate number of intractable proteins with multiple transmembrane regions and variable, or undefined glycosylation patterns, which impede protein preparation and crystallization, in such druggable proteins. We stress the importance of structural analysis of proteins, especially approved-drug target proteins, and the development of new methods to... (More)
We identified six groups of diseases expected to cause serious future health issues on the basis of a WHO report. Approved drugs for these diseases were associated with 409 target proteins; however, the percentage of selected proteins with full-length structural information deposited in the Protein Data Bank (PDB) was only 9.8%. The reason for the low percentage may be as a result of a disproportionate number of intractable proteins with multiple transmembrane regions and variable, or undefined glycosylation patterns, which impede protein preparation and crystallization, in such druggable proteins. We stress the importance of structural analysis of proteins, especially approved-drug target proteins, and the development of new methods to enable structural analyses of presently intractable proteins. In addition, we present an overview of large structural biology projects.
(Less)
- author
- Mori, Masumi ; Ogawa, Naoko ; Tanikawa, Kunihiro ; Dodo, Sanae ; Shibayama, Sotaro LU ; Yokoyama, Shigeyuki and Tanaka, Akiko
- publishing date
- 2008-06
- type
- Contribution to journal
- publication status
- published
- subject
- in
- Drug Discovery Today
- volume
- 13
- issue
- 11-12
- pages
- 4 pages
- publisher
- Elsevier
- external identifiers
-
- pmid:18549971
- scopus:44649193825
- ISSN
- 1359-6446
- DOI
- 10.1016/j.drudis.2008.03.008
- language
- English
- LU publication?
- no
- id
- 10c32959-bc4f-4c8d-bb81-ddf742ee84d9
- date added to LUP
- 2017-04-13 17:48:45
- date last changed
- 2024-01-13 18:49:46
@article{10c32959-bc4f-4c8d-bb81-ddf742ee84d9,
abstract = {{<p>We identified six groups of diseases expected to cause serious future health issues on the basis of a WHO report. Approved drugs for these diseases were associated with 409 target proteins; however, the percentage of selected proteins with full-length structural information deposited in the Protein Data Bank (PDB) was only 9.8%. The reason for the low percentage may be as a result of a disproportionate number of intractable proteins with multiple transmembrane regions and variable, or undefined glycosylation patterns, which impede protein preparation and crystallization, in such druggable proteins. We stress the importance of structural analysis of proteins, especially approved-drug target proteins, and the development of new methods to enable structural analyses of presently intractable proteins. In addition, we present an overview of large structural biology projects.</p>}},
author = {{Mori, Masumi and Ogawa, Naoko and Tanikawa, Kunihiro and Dodo, Sanae and Shibayama, Sotaro and Yokoyama, Shigeyuki and Tanaka, Akiko}},
issn = {{1359-6446}},
language = {{eng}},
number = {{11-12}},
pages = {{469--472}},
publisher = {{Elsevier}},
series = {{Drug Discovery Today}},
title = {{Contribution of structural biology to clinically validated target proteins}},
url = {{http://dx.doi.org/10.1016/j.drudis.2008.03.008}},
doi = {{10.1016/j.drudis.2008.03.008}},
volume = {{13}},
year = {{2008}},
}